FDA approves breakthrough cancer drug months ahead of schedule: ‘Unprecedented results’
al.com
—
The FDA approved the medication more than six months ahead of schedule after trials showed it nearly doubled median survival to 13.2 months versus 6.7 months with chemotherapy.